Repligen (RGEN) Reports In-Line Q3 EPS

Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $15.3 million versus the consensus estimate of $15.6 million.

Repligen sees FY2014 revenue of $60-62 million, versus prior guidance of $59-62 million and the consensus of $0.28 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Wolverine World Wide (WWW) PT Raised to $26 at Stifel as Multiple Can Move Higher
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c